The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

OGFR  -  opioid growth factor receptor

Homo sapiens

Synonyms: 7-60, OGFr, Opioid growth factor receptor, Protein 7-60, Zeta-type opioid receptor
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of OGFR


High impact information on OGFR


Chemical compound and disease context of OGFR


Biological context of OGFR

  • Functional studies using antisense oligonucleotides to OGFr demonstrated an enhancement in cell growth [8].
  • Receptor affinity and the gene expression of OGFr mRNA were unchanged in tumors of different sizes [9].
  • Potential involvement of OGFr in the depletion of mucous cells during prolonged and heavy G. salaris infection, via suppression of DNA synthesis and profound decrease in basal cell proliferation, is proposed [10].
  • Large tumors had a reduction of 3- to 7-fold in OGFr binding sites relative to small tumors, and medium size tumors showed a progressive diminishment in OGF receptors that ranged between that of small and large neoplasias [9].
  • Visual acuity and its meridional variations in children aged 7-60 months [11].

Anatomical context of OGFR

  • Immunocytochemistry demonstrated the presence of both opioid growth factor and OGFr within the endothelial cells and mesenchymal cells of the developing chorioallantoic membrane vessel wall [12].
  • Conversely, corneas transfected with antisense constructs of OGFr had corneal defects that were 56% and 48% smaller than the EV group at 16 and 24 hours, respectively [13].
  • The median time between aspirin withdrawal and lower limb ischemia was 23 days (range, 7-60 days) [14].
  • Treatment with antisense OGFr oligonucleotides increased the number of cells by over 2-fold compared to wild-type cultures of COS-7 cells and preparations receiving scrambled oligonucleotides [15].
  • Sixteen patients developed coronary artery disease (CAD) manifesting itself 7-60 months after HTx (20.7%) [16].

Associations of OGFR with chemical compounds

  • Ornidazole was administered at a dose of 500 mg every 12 h i.v. or/and orally, and clindamycin 600 mg every 8 h i.v. for 7-60 days [17].
  • Packing densities of aldehyde groups on the activated agarose surface could be controlled in a gel range of 7-60 micromol/ml aldehyde by the amount of glycidol used [18].
  • Di-n-butyl phthalate (DBP) was detected at a concentration of 7-60 ng/ml in most intravenous injection solutions in plastic containers, but it was not detected in solutions in glass bottles [19].
  • Laboratory evaluation revealed a morning cortisol concentration of <0.1 microg/dl (normal range [n.r.]: 4.3-22.4 microg/dl) and a simultaneous ACTH concentration of 2 pg/ml (n.r. 25-62 pg/ml); FSH 66.8 IU/l (n.r. for age: 1-12.8 IU/l); LH 41.1 IU/l (n.r. for age: 1-12 IU/l); E2 38 pg/ml (n.r. for age: 7-60 pg/ml) [20].

Analytical, diagnostic and therapeutic context of OGFR

  • Expression of opioid growth factor receptor correlated with a longer recurrence-free period in basal cell carcinoma that recurred after radiotherapy (Kaplan-Meier analysis, P = 0.041) [2].
  • To investigate the relationship of OGFr to advancement of human pancreatic and colon cancers, tumor cells were transplanted into nude mice, and small, medium, and large neoplasias were assessed for OGFr number and affinity by receptor binding analysis, and for gene expression of OGFr mRNA by Northern blot analysis [21].
  • Gene therapy to reinstate more OGFr, and thus enhance OGFr function, could serve as a useful treatment for inhibiting tumor progression [9].
  • A case-control study was conducted among patients aged 7-60 yrs, who attended Wagga Hospital (NSW, Australia) for asthma during the period of 1 June 1997 to 31 October 1997 [22].
  • The OGFr number of the SCCHN tumors was 2.1-fold greater in the animals exposed to OGF or paclitaxel, and elevated 38% in the paclitaxel/OGF group; significant differences from the control group were found for the OGF and paclitaxel groups [23].


  1. Reversal of protein-energy malnutrition in children during treatment of advanced neoplastic disease. Rickard, K.A., Grosfeld, J.L., Kirksey, A., Ballantine, T.V., Baehner, R.L. Ann. Surg. (1979) [Pubmed]
  2. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Urosevic, M., Oberholzer, P.A., Maier, T., Hafner, J., Laine, E., Slade, H., Benninghoff, B., Burg, G., Dummer, R. Clin. Cancer Res. (2004) [Pubmed]
  3. Benign noninflammatory bronchial stenosis: treatment with balloon dilation. Ferretti, G., Jouvan, F.B., Thony, F., Pison, C., Coulomb, M. Radiology. (1995) [Pubmed]
  4. Racial and gender differences in the incidence of recurrent venous thromboembolism. White, R.H., Dager, W.E., Zhou, H., Murin, S. Thromb. Haemost. (2006) [Pubmed]
  5. Hypothalamic-pituitary-adrenal axis dysfunction in critically ill patients with traumatic brain injury: incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin-6 levels. Dimopoulou, I., Tsagarakis, S., Kouyialis, A.T., Roussou, P., Assithianakis, G., Christoforaki, M., Ilias, I., Sakas, D.E., Thalassinos, N., Roussos, C. Crit. Care Med. (2004) [Pubmed]
  6. Reepithelialization of the human cornea is regulated by endogenous opioids. Zagon, I.S., Sassani, J.W., McLaughlin, P.J. Invest. Ophthalmol. Vis. Sci. (2000) [Pubmed]
  7. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. McLaughlin, P.J., Stack, B.C., Braine, K.M., Ruda, J.D., Zagon, I.S. Int. J. Oncol. (2004) [Pubmed]
  8. Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans. Zagon, I.S., Verderame, M.F., Allen, S.S., McLaughlin, P.J. Brain Res. (2000) [Pubmed]
  9. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor. McLaughlin, P.J., Zagon, I.S. Int. J. Oncol. (2006) [Pubmed]
  10. Gene expression profiles of some immune relevant genes from skin of susceptible and responding Atlantic salmon (Salmo salar L.) infected with Gyrodactylus salaris (Monogenea) revealed by suppressive subtractive hybridisation. Matejusová, I., Felix, B., Sorsa-Leslie, T., Gilbey, J., Noble, L.R., Jones, C.S., Cunningham, C.O. Int. J. Parasitol. (2006) [Pubmed]
  11. Visual acuity and its meridional variations in children aged 7-60 months. Birch, E.E., Gwiazda, J., Bauer, J.A., Naegele, J., Held, R. Vision Res. (1983) [Pubmed]
  12. Opioid growth factor modulates angiogenesis. Blebea, J., Mazo, J.E., Kihara, T.K., Vu, J.H., McLaughlin, P.J., Atnip, R.G., Zagon, I.S. J. Vasc. Surg. (2000) [Pubmed]
  13. Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Zagon, I.S., Sassani, J.W., Malefyt, K.J., McLaughlin, P.J. Arch. Ophthalmol. (2006) [Pubmed]
  14. Aspirin withdrawal and acute lower limb ischemia. Albaladejo, P., Geeraerts, T., Francis, F., Castier, Y., Lesèche, G., Marty, J. Anesth. Analg. (2004) [Pubmed]
  15. The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells. Zagon, I.S., Verderame, M.F., McLaughlin, P.J. Neuropeptides (2003) [Pubmed]
  16. The influence of rejection episodes on the development of coronary artery disease after heart transplantation. Schütz, A., Kemkes, B.M., Kugler, C., Angermann, C., Schad, N., Rienmüller, R., Fritsch, S., Anthuber, M., Neumaier, P., Gokel, J.M. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. (1990) [Pubmed]
  17. Ornidazole versus clindamycin: comparative evaluation in the treatment of 140 serious anaerobic infections. Giamarellou, H., Volanaki, M., Avlami, A., Tsatsiadis, K., Petrochilos, E., Daikos, G.K. Chemotherapy. (1982) [Pubmed]
  18. Enzymic cleavage of fusion protein using immobilized urokinase covalently conjugated to glyoxyl-agarose. Suh, C.W., Choi, G.S., Lee, E.K. Biotechnol. Appl. Biochem. (2003) [Pubmed]
  19. Simple and rapid analysis of endocrine disruptors in liquid medicines and intravenous injection solutions by automated in-tube solid-phase microextraction/high performance liquid chromatography. Mitani, K., Narimatsu, S., Izushi, F., Kataoka, H. Journal of pharmaceutical and biomedical analysis. (2003) [Pubmed]
  20. Autoimmune polyglandular endocrinopathy and anterior hypophysitis in a 14 year-old girl presenting with delayed puberty. Cemeroglu, A.P., Böber, E., Dündar, B., Büyükgebiz, A. Journal of pediatric endocrinology & metabolism : JPEM. (2001) [Pubmed]
  21. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. Zagon, I.S., McLaughlin, P.J. Int. J. Oncol. (2006) [Pubmed]
  22. Thunderstorm-associated asthma in an inland town in south-eastern Australia. Who is at risk? Girgis, S.T., Marks, G.B., Downs, S.H., Kolbe, A., Car, G.N., Paton, R. Eur. Respir. J. (2000) [Pubmed]
  23. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Jaglowski, J.R., Zagon, I.S., Stack, B.C., Verderame, M.F., Leure-duPree, A.E., Manning, J.D., McLaughlin, P.J. Cancer Chemother. Pharmacol. (2005) [Pubmed]
WikiGenes - Universities